// App-Quantinova.ai

: Mepolizumab improves activity limitation in severe eosinophilic asthma

Researchers

Presenter

  • Frank Albers

Principal Investigators

  • Linda M Nelsen

  • Daniel J Bratton

  • Eric S Bradford

  • G J Braunstahl

Medical Centers

  • Respiratory Medical Franchise, GSK, Research Triangle Park, NC, United States,

  • Value Evidence & Outcomes, GSK, Collegeville, PA, United States,

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, United States.

  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands

Locations

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Recepteur d'Origine Nantais

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • NCT02281318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved